MARKET

CALC

CALC

CALCIMEDICA INC
NASDAQ
4.370
-0.200
-4.38%
After Hours: 4.370 0 0.00% 16:10 12/05 EST
OPEN
4.570
PREV CLOSE
4.570
HIGH
4.570
LOW
4.260
VOLUME
61.22K
TURNOVER
--
52 WEEK HIGH
4.815
52 WEEK LOW
1.420
MARKET CAP
62.97M
P/E (TTM)
-2.7307
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CALC last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at CALC last week (1117-1121)?
Weekly Report · 11/24 09:55
Oppenheimer Reaffirms Their Buy Rating on CalciMedica (CALC)
TipRanks · 11/17 13:55
Weekly Report: what happened at CALC last week (1110-1114)?
Weekly Report · 11/17 09:55
CalciMedica GAAP EPS of -$0.52
Seeking Alpha · 11/12 14:54
CalciMedica Reports Q3 2025 Results and Advances Auxora Clinical Programs
Reuters · 11/12 12:16
CalciMedica reports Q3 net loss of $7.8 mln
Reuters · 11/12 12:15
CalciMedica announces publication in JCI preclinical study of CM5480
TipRanks · 11/12 12:10
More
About CALC
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Webull offers Calcimedica Inc stock information, including NASDAQ: CALC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CALC stock methods without spending real money on the virtual paper trading platform.